Data as of Jul 25
| -0.10 / -0.90%|
The 1 analysts offering 12-month price forecasts for MusclePharm Corp have a median target of 16.00, with a high estimate of 16.00 and a low estimate of 16.00. The median estimate represents a +45.45% increase from the last price of 11.00.
The current consensus among 2 polled investment analysts is to Buy stock in MusclePharm Corp. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.